0.2793
전일 마감가:
$0.272
열려 있는:
$0.27
하루 거래량:
819.69K
Relative Volume:
0.27
시가총액:
$59.33M
수익:
-
순이익/손실:
$-41.23M
주가수익비율:
-0.399
EPS:
-0.7
순현금흐름:
$-11.54M
1주 성능:
-21.92%
1개월 성능:
-3.66%
6개월 성능:
-63.40%
1년 성능:
-81.98%
Renovaro Inc Stock (RENB) Company Profile
명칭
Renovaro Inc
전화
45 39179840
주소
CENTURY CITY MEDICAL PLAZA, SUITE 906 LOS ANGELES
RENB을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
RENB
Renovaro Inc
|
0.2793 | 59.33M | 0 | -41.23M | -11.54M | -0.70 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Renovaro Inc 주식(RENB)의 최신 뉴스
Renovaro Inc (RENB Stock: A Sea of Opportunity - investchronicle.com
Ratios Uncovered: Breaking Down Renovaro Inc (RENB)’s Trailing Twelve Months Metrics - DWinneX
Renovaro Obtains a U.S. Patent for its AI-Powered Platform for Medication Discovery and Diagnostics - MSN
Smart Healthcare Is Taking Over. Here's Where the Money's Headed - Finansavisen
Renovaro Inc. (NASDAQ:RENB) Shares Bought by Nuveen Asset Management LLC - Defense World
POAIRenovaro Issues Shareholder Letter and Provides Corporate Update - Revista ADVFN
Renovaro Biosciences Subsidiary CEO Resigns Abruptly - TipRanks
Deutsche Bank AG Takes $107,000 Position in Renovaro Inc. (NASDAQ:RENB) - Defense World
Renovaro subsidiary secures patent for drug discovery AI By Investing.com - Investing.com South Africa
RENB stock touches 52-week low at $0.27 amid market challenges - Investing.com Australia
Renovaro's BioSymetrics Unit Gets Notice of Allowance for New Patent - MarketScreener
Renovaro (RENB) Secures Patent to Enhance AI in Drug Discovery | - GuruFocus
Renovaro Inc. Skyrockets on AI Patent Win: What’s Fueling the Frenzy? - RagingBull
Renovaro (RENB) Secures Patent to Enhance AI in Drug Discovery | RENB Stock News - GuruFocus
Renovaro Secures Key U.S. Patent to Strengthen AI-Driven Drug Di - GuruFocus
Renovaro subsidiary secures patent for drug discovery AI - Investing.com
Renovaro secures U.S. patent for AI-driven drug discovery, diagnostics platform - TipRanks
Renovaro Secures Key U.S. Patent to Strengthen AI-Driven Drug Discovery and Diagnostics Platform | RENB Stock News - GuruFocus
Renovaro Secures Key U.S. Patent to Strengthen AI-Driven Drug Discovery and Diagnostics Platform - GlobeNewswire
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Purchases 41,296 Shares of Renovaro Inc. (NASDAQ:RENB) - Defense World
Renovaro Inc. (NASDAQ:RENB) Shares Acquired by Northern Trust Corp - Defense World
Contrasting Stoke Therapeutics (NASDAQ:STOK) & Renovaro (NASDAQ:RENB) - Defense World
What Analysts Think About Renovaro Inc (NASDAQ: RENB)’s Potential Raise - Stocksregister
Court Denies Renovaro Motion for an Expedited Trial in July - GlobeNewswire
Predictive Oncology says court denies Renovaro motion for expedited trial - TipRanks
Predictive Oncology to defend against Renovaro’s claims in court By Investing.com - Investing.com Canada
Predictive Oncology (POAI) Addresses Legal Dispute with Renovaro - GuruFocus
Predictive Oncology to defend against Renovaro’s claims in court - Investing.com Australia
Court Denies Renovaro Motion for an Expedited Trial in July | POAI Stock News - GuruFocus
Delaware Court Rejects Renovaro's Rush to Trial Against Predictive Oncology, Cites Critical Delays - Stock Titan
Court Denies Renovaro Motion for an Expedited Trial in July | P - GuruFocus
Renovaro Inc. Accelerates 2025 Lawsuit to Force Predictive Oncology Merger - MSN
Major Moves And Shakes In Health Care Sector - Finimize
AI Could Add $461 Billion to Global Healthcare--And These New Platforms Are Leading the Charge - Nasdaq
Predictive Oncology Stock Hits 1-Month Low Amid Renovaro Legal Clash, But Retail Leans Bullish By Stocktwits - Investing.com India
UPDATERenovaro Inc. Announces Expedited Trial for 2025 Lawsui - GuruFocus
Court Fast-Tracks Renovaro's Lawsuit to Force Merger After Predictive Oncology's $545K Securities Breach - Stock Titan
Renovaro Sues Predictive Oncology (POAI) Over Merger Agreement D - GuruFocus
Renovaro Gets Expedited Trial in Predictive Oncology Merger Dispute - marketscreener.com
Renovaro announces expedited trial on suit to enforce Predictive Oncology merger - TipRanks
Renovaro Inc. Announces Expedited Trail for 2025 Lawsuit to Enforce Binding Merger Agreement with Predictive Oncology - The Manila Times
Renovaro Inc. Announces Expedited Trail for 2025 Lawsuit to Enforce Binding Merger Agreement with Predictive Oncology | RENB Stock News - GuruFocus
Renovaro Inc. Secures Ruling to Expedite Trial Against Predictive Oncology Over Breach of Merger Agreement - Nasdaq
Renovaro Inc (RENB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Renovaro Inc 주식 (RENB) 내부자 거래
내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
---|---|---|---|---|---|---|---|
William Anderson Wittekind | 10% Owner |
Jul 17 '24 |
Sale |
1.46 |
16,362 |
23,889 |
841,433 |
William Anderson Wittekind | 10% Owner |
Jul 15 '24 |
Sale |
1.41 |
21,954 |
30,955 |
875,795 |
William Anderson Wittekind | 10% Owner |
Jul 10 '24 |
Sale |
1.51 |
75,000 |
113,250 |
894,645 |
William Anderson Wittekind | 10% Owner |
Jul 11 '24 |
Sale |
1.51 |
14,896 |
22,493 |
897,749 |
William Anderson Wittekind | 10% Owner |
Jul 09 '24 |
Sale |
1.53 |
4,630 |
7,084 |
969,645 |
William Anderson Wittekind | 10% Owner |
Jul 05 '24 |
Sale |
1.55 |
60,000 |
93,000 |
974,275 |
William Anderson Wittekind | 10% Owner |
Jul 03 '24 |
Sale |
1.51 |
50,000 |
75,500 |
1,034,275 |
자본화:
|
볼륨(24시간):